Effects of one-year tofacitinib therapy on bone metabolism in rheumatoid arthritis.
A HamarZoltán SzekaneczA PusztaiM CzókolyováE VéghZ PethőN BodnárK GulyásÁ HorváthB SoósL BodokiH P BhattoaG NagyG TajtiG PanyiÉ SzekaneczA DomjánK HodosiS SzántóG SzűcsS SzamosiPublished in: Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA (2021)
One-year tofacitinib treatment stabilized BMD in RA patients and resulted in a positive balance of bone turnover as indicated by bone biomarkers. Further studies are needed to evaluate the potential beneficial effects of JAK inhibitors on inflammatory bone loss.
Keyphrases
- bone loss
- rheumatoid arthritis
- bone mineral density
- disease activity
- end stage renal disease
- ejection fraction
- postmenopausal women
- newly diagnosed
- soft tissue
- chronic kidney disease
- ankylosing spondylitis
- interstitial lung disease
- bone regeneration
- body composition
- prognostic factors
- peritoneal dialysis
- patient reported outcomes
- systemic lupus erythematosus
- combination therapy
- patient reported
- idiopathic pulmonary fibrosis